Optimized Transcriptional Signature for Evaluation of MEK/ERK Pathway Baseline Activity and Long-Term Modulations in Ovarian Cancer

Mikhail S. Chesnokov(University of Minnesota), Ilana Chefetz(Mercer University)
International Journal of Molecular Sciences
November 1, 2022
10.3390/ijms232113365
Cited by 11

Related Papers

The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma
|Cancers|2021|29
Optimized transcriptional signature for evaluation of MEK/ERK pathway baseline activity and long-term modulations in ovarian cancer
|bioRxiv (Cold Spring Harbor Laboratory)|2022|1